Updates are available Correction dated 2019-05-17

Article History

Received: 26 December 2018

Accepted: 18 February 2019

First Online: 17 April 2019

Change Date: 17 May 2019

Change Type: Correction

Change Details: After publication of the original article 1, the authors have notified us that the row corresponding to the “Alniditan” drug shouldn’t have been included in Table 1. Table 1 should therefore be presented as below:

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: MA is a consultant or scientific advisor for Allergan, Amgen, Alder, Eli Lilly, Novartis and Teva, principal investigator for: Amgen 20,120,178 (Phase 2), 20,120,295 (Phase 2), 20,130,255 (Open label extension), 20,120,297 (Phase 3), 20,150,308 (Phase 2), ElectroCore GM-11 gamma-Core-R, TEVA TV48125-CNS-30068 (Phase 3), Novartis CAMG334A2301 (Phase 3) and Alder PROMISE-2. MA has no ownership interest and does not hold stock in any pharmaceutical company. MA serves as associated editor of Cephalalgia and co-editor of the Journal of Headache and Pain and is Editor for the thematic series 'The changing face of migraine'. TPD and SG report no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.